Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (hMSCs) in Patients With Ischemic Heart Failure With Reduced Ejection Fraction (HFrEF)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

13 Feb 2025 According to a BioCardia media release, the first DSMB review is expected to take place in March 2025.
13 Feb 2025 According to a BioCardia media release, enrollment and dosing in the low dose cohort in CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial has been completed.
24 Dec 2024 Planned number of patients changed from 9 to 39, Randomized and Parallel has been added in design terms.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com